BioIVT Acquires XenoTech from Sekisui Chemical
September 12, 2022
BioIVT has acquired XenoTech, a Kansas City–based provider of ADME‑Tox in vitro models and contract research services, from Sekisui Chemical. The acquisition expands BioIVT's hepatic product portfolio and ADME/DMPK capabilities to better support biopharma customers' preclinical testing needs. Financial terms were not disclosed.
- Buyers
- BioIVT
- Targets
- XenoTech
- Sellers
- Sekisui Chemical
- Industry
- Biotechnology
- Location
- Kansas, United States
- Transaction Type
- Divestiture
Explore More
Related Acquisitions
-
BioIVT Acquires ZenBio
August 21, 2024
Healthcare Services
BioIVT has acquired ZenBio, a Durham-based provider of advanced cell products and biospecimen services, to expand its skin-based expertise, primary cell and exosome isolation capabilities, and blood product offerings for pharmaceutical and cosmetics research. The deal strengthens BioIVT's service portfolio and complements recent integrations to accelerate support for drug discovery and cosmeceutical development; financial terms were not disclosed.
-
BioIVT Acquires Valley Biomedical Products & Services
June 28, 2021
Medical Devices
BioIVT, a provider of research models and value-added research services, has acquired Valley Biomedical Products & Services, an FDA-registered manufacturer of in vitro diagnostics, sera, plasma and reagents based in Winchester, Virginia. The acquisition will expand BioIVT’s capabilities in IVD manufacturing and cell & gene therapy support by combining Valley Biomedical’s reagent and blood-product manufacturing with BioIVT’s donor centers and specimen services; BioIVT will continue operating the Winchester facility and retain its staff.
-
BioIVT Acquires BeCytes Biotechnologies
November 4, 2025
Biotechnology
BioIVT has acquired BeCytes Biotechnologies, a Barcelona-based provider of ethically sourced human tissues and primary cell isolation services. The deal expands BioIVT's European footprint and strengthens its capabilities for New Approach Methodologies (NAMs) and ADME research; BeCytes will continue to operate from Barcelona and financial terms were not disclosed.
-
Medix Biochemica Group Acquires Bioresource Technology (BRT)
June 21, 2022
Biotechnology
Medix Biochemica has acquired a 100% stake in US-based Bioresource Technology (BRT) to expand its base matrix capabilities and strengthen its presence in the United States. BRT will be integrated into Medix Biochemica’s IVD Biomaterials Business Unit (St. Louis) while operations continue in Weston, Florida, and BRT leadership will serve as strategic advisors.
-
BioIVT Acquires PrecisionMed
July 18, 2023
Healthcare Services
BioIVT, a global biospecimen solutions provider, has acquired PrecisionMed, LLC, a Carlsbad-based supplier of high-quality human biospecimens and owner of a large longitudinal cerebrospinal fluid (CSF) repository. The acquisition expands BioIVT's supply network, inventory and capacity for CSF and liquid biopsy products while PrecisionMed will continue to operate from its existing headquarters and collection sites.
-
Discovery Life Sciences Acquires In Vitro ADMET Laboratories (IVAL)
December 2, 2021
Healthcare Services
Discovery Life Sciences has acquired Maryland-based In Vitro ADMET Laboratories (IVAL) to add the world’s largest hepatocyte inventory and leading in vitro ADMET expertise. IVAL founder Albert P. Li, Ph.D. will join Discovery as Chief Scientific Officer of Pharmacology and Toxicology as Discovery expands its biospecimen and biomarker service capabilities to better support drug metabolism, toxicology, and pharmacology testing for pharma customers.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.